Ingen appoints director of r&d
Aims to increase sales of in vitro diagnostic (IVD) kits
Mignon-Godefroy joins the firm to generate sales of its first proprietary in vitro diagnostic (IVD) kit. These IVD kits are based on the firm’s specialist knowledge in proteomics and expertise in synthesising new recombinant antigens. Mignon-Godefroy will be responsible for identifying clinically relevant recombinant antigens as potential markers for the detection of infectious diseases found in prosthetic replacements, and to develop innovative IVD kits for clinical use.
‘Dr Mignon-Godefroy’s 15 years’ experience in biotechnology, depth of knowledge and skills will be a major contribution to our on-going r&d efforts,’ said Jean-Pierre Hermet, chief executive of Ingen Biosciences. ‘Her arrival will also strengthen the team, which has made significant inroads into developing products based on innovative technologies.'
Mignon-Godefroy joins Ingen Biosciences from the blood virus division of Bio-Rad, a manufacturer and distributor of products for a range of technologies including proteomics, where she was director of international projects.
You may also like
Research & Development
ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology
Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development
Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease
Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
Manufacturing
LabVantage Solutions introduces LabVantage CORTEX, advancing its LIMS platform for AI-driven laboratory operations
Next-Generation Platform Extends LIMS with Agentic AI and Cloud-Native Automation to Improve Efficiency, Reduce Errors and Gain Deeper Insight from Data. Learn More from LabVantage Leadership at Pittcon 2026
Manufacturing
Schütz to build automated IBC production facility at BASF's Ludwigshafen headquarters
Packaging specialist Schütz has signed an agreement with BASF to construct a highly automated intermediate bulk container manufacturing and storage facility directly adjacent to the chemical giant's main plant in Ludwigshafen, enabling round-the-clock just-in-time delivery
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258
The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists